onepharm is an innovative pharmaceutical company with a focus on chemical, clinical, and formulation development of small molecule drugs for the treatment of viral diseases. The company was founded in 2005 and is owned by its Management Team and Green Hills Biotechnology.
Together with Elivir and Glycyrrhizin, onepharm has acquired and has plans to develop a product portfolio of small molecules that allows direct entry into preclinical and clinical trials for major viral diseases. Indications for the drugs are focused on the respiratory tract, e.g, rhinovirus, influenza virus, avian flu virus and SARS coronavirus (CoV).
In addition, onepharm's research programs will provide new lead compounds with antiviral activity and potentially identify additional therapeutic indications for onepharm's molecular substance library.
To strenghten onepharms research position, collaborations with major Austrian academic institutions such as the University of Technology, the University of Applied Life Sciences, the Medicinal University, all in Vienna, have been established. Research partnerships with the Goethe University in Frankfurt, Germany and the Leopold Franzens University in Innsbruck, Austria, are also in place. onepharm holds the patents or the exclusive global rights to use their substances in the respective pharmacological indication.
Last Updated: 11-08-05